AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06536413
Drug: All-Trans Retinoic Acid (ATRA) Dose 0
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses.
Trial: NCT06536413
Drug: All-Trans Retinoic Acid (ATRA) Dose -1
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.
Trial: NCT06793475
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib 27mg/m\^2 will be administered by i.v. on Days 1,2,8,9 during bridging therapy.
Trial: NCT06793475
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide (150mg/d) will be administered by p.o. on Days 1-14 during bridging therapy, and Days 1-28 every 28-day cycle during maintanance treatment.
Trial: NCT06536413
Drug: All-Trans Retinoic Acid (ATRA) Dose 1
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.
Trial: NCT06793475
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (20mg/d) will be administered by i.v. or p.o. on Days 1-4,8,9 during bridging therapy.
Trial: NCT04958122
Drug: Cefixime 400mg
RxNorm normalized name: CEFIXIME 400MG TAB
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefixime 400 mg, one capsule, twice a day for 10 days
Trial: NCT05534750
Drug: Tedizolid arm (SIVEXTRO®)
RxNorm normalized name: Tedizolid
DrugBank: Tedizolid phosphate (DB09042)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Trial: NCT05534750
Drug: Linezolid arm (ZYVOXID®)
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
Trial: NCT04973657
Drug: VK0214
RxNorm normalized name: VK0214
DrugBank: VK-0214 (DB17670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: API in capsule
Trial: NCT05708755
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delivered as standard of care for post-lung transplant immunosuppression and infection prophylaxis. Started on the first day post-transplant at a standard dose of 900 mg daily and continued for 12 months. Dose adjustments may be necessary based on renal function and/or adverse effects (e.g. neutropenia). Dose adjustments are standard based on package insert recommendations.
Trial: NCT06114238
Drug: Itepekimab AI
RxNorm normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous AI
Trial: NCT06114238
Drug: Itepekimab PFS
RxNorm normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection; Route of administration: Subcutaneous PFS
Trial: NCT05609565
Drug: spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spinal anesthesia with hyperbaric prilocaine+adductor canal block (ACB) with bupivacaine
Trial: NCT05609565
Drug: spinal anesthesia with bupivacaine
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spinal anesthesia with bupivacaine
Trial: NCT06010719
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care. A 7-day, twice-daily course of amoxicillin will be offered as a syrup to children (80 mg/kg divided into twice-daily doses, estimated with weight-based dosing).
Trial: NCT06794086
Drug: PD-1 Monoclonal Antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 monoclonal antibody is a type of immunotherapy drug designed to treat various cancers by targeting the programmed death receptor-1 (PD-1) pathway.The PD-1 monoclonal antibody used in this study is sintilimab at a dose of 200 mg, administered via intravenous infusion on Day 1. Participants will be considered eligible only if they have completed four or more cycles of PD-1 monoclonal antibody treatment both before and after SBRT.
Trial: NCT06795204
Drug: Moxifloxacin Hydrochloride
RxNorm normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Positive Control
Trial: NCT06184503
Drug: Velmanase Alfa
RxNorm normalized name: Velmanase alfa
DrugBank: Velmanase alfa (DB12374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
Trial: NCT06572111
Drug: BI 1839100
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1839100
Trial: NCT06572111
Drug: BI 1839100 (C-14) formulation 2
RxNorm normalized name: Bis(2-benzothiazolyl) disulfide
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BI 1839100 (C-14) formulation 2
Trial: NCT04995497
Drug: Intravenous Administration of Lidocaine Post Cardiac Surgery
RxNorm normalized name: post oak pollen extract
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine will be administered via intravenously. Initial dose will be at 2 mg/kg ideal body weight followed by dosing at 2 mg/kg/hr for 48 hours
Trial: NCT04995497
Drug: Administration of Lidocaine Post Cardiac Surgery via ESP Catheter
RxNorm normalized name: post oak pollen extract
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine will be administered via ESP catheter. Initial dose will be at 2 mg/kg ideal body weight split between two catheters followed by dosing at 2 mg/kg/hr for 48 hours
Trial: NCT06061809
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
Trial: NCT06061809
Drug: PD-L1 t-haNK
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive PD-L1 t-haNK (\~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
Trial: NCT06061809
Drug: N-803
RxNorm normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
Trial: NCT04607005
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
Trial: NCT06788158
Drug: Incobotulinum Toxin A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: will be administered 2 ampoules (200 IU) of Incobotulinum toxin , injectable solution presentation 100 IU ampoule with powder diluted in 1 ml of 0.9% saline solution in a single application at 4 points, in addition to a therapeutic exercise program in the teaching service to later do it at home that will be done daily for 4 months (cryotherapy for 15 minutes on the plantar fascia, active mobilizations of the ankle and foot for 5 minutes, stretching exercises for the triceps surae and plantar fascia for 20 seconds, 3 repetitions, strengthening of intrinsic muscles of the foot).
Trial: NCT06796517
Drug: CAR-T Therapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.
Trial: NCT06796517
Drug: Bispecific antibody
RxNorm normalized name: Bispecific antibody 520c9x22
DrugBank: MDX-210 (DB17250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.
Trial: NCT06796517
Drug: Antibody-Drug Conjugate
RxNorm normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.
Trial: NCT06796517
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
DrugBank: Anti-GD2 monoclonal antibody 3F8 (DB15388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.
Trial: NCT05126901
Drug: Ferric Maltol
RxNorm normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID.
Trial: NCT05126901
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID.
Trial: NCT05837091
Drug: Low Sodium Oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrated according to standard of care and continued on stable dose for 3 months
Trial: NCT06483880
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive albendazole therapy at the recommended dosage.
Trial: NCT06793332
Drug: Ivonescimab Combined With TROP2 ADC
RxNorm normalized name: miconazole
DrugBank: Ivonescimab (DB18931)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;
Trial: NCT02915198
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study medication dose may be increased by a step-wise fashion up to a maximum of 4 tablets per day.
Trial: NCT05999396
Drug: Administration of CC-3
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated titration phase, Standard 3+3 titration phase, expansion phase
Trial: NCT04720183
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.
Trial: NCT05110495
Drug: Xentuzumab
RxNorm normalized name: Xentuzumab
DrugBank: Xentuzumab (DB14871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
Trial: NCT06679140
Drug: ibuzatrelvir
RxNorm normalized name: Ibuzatrelvir
DrugBank: Ibuzatrelvir (DB19451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuzatrelvir tablets
Trial: NCT05538741
Drug: Bolus of remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.19-0.25 mg/kg for 60-80 years old 0.14-0.19 mg/kg for \>80 years old
Trial: NCT06377696
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT06478212
Drug: Vorasidenib
RxNorm normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be taken by mouth once daily in 28-day cycles with no break between cycles
Trial: NCT06478212
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To be taken by mouth once daily for the first 5 days of each 28-day cycle, for a maximum of 12 cycles
Trial: NCT05538741
Drug: Continuous infusion of remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg/kg/hr until loss of consciousness
Trial: NCT04953780
Drug: Calaspargase pegol-mknl
RxNorm normalized name: calaspargase pegol-mknl
DrugBank: Calaspargase pegol (DB14730)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calaspargase pegol-mknl
Trial: NCT04998604
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: solution for injection subcutaneous
Trial: NCT04998604
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: solution for injection subcutaneous
Trial: NCT05673057
Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
RxNorm normalized name: Muromonab-Cd3
DrugBank: Muromonab (DB00075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated.
Trial: NCT05724329
Drug: Tislelizumab + Dasatinib + Quercetin (neoadjuvant)
RxNorm normalized name: Tislelizumab
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receive Tislelizumab (IV) on day 1, dasatinib (PO) on day 1,2,3 and quercetin (PO) on day 1,2,3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT05724329
Drug: Tislelizumab + Dasatinib + Quercetin (adjuvant)
RxNorm normalized name: Tislelizumab
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tislelizumab (200 mg, day=1) Cycle=1-15cycle Dasatinib (100mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10 Quercetin (1250mg/day, day= 1,2,3) Cycle=1、2、3、8、9、10
Trial: NCT06794450
Drug: Neostigmine + Atropine
RxNorm normalized name: atropine / neostigmine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient in active comparators arms will receive i.v. neostigmine 60 mcg/kg along with 0.4 mg of atropine sulfate per 1 mg of neostigmine at the end of operating procedure from the point at which a Train-of-Four Count (TOFC) of 2 is observed
Trial: NCT06793150
Drug: dexmedetomidin
RxNorm normalized name: Dexmedetomidin
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
Trial: NCT04736966
Drug: Guselkumab 30mg
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30mg of Guselkumab administered by subcutaneous injection
Trial: NCT04736966
Drug: Guselkumab 70mg
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 70mg of Guselkumab administered by subcutaneous injection
Trial: NCT04736966
Drug: Guselkumab 100mg
RxNorm normalized name: GUSELKUMAB 100MG/ML INJ 1ML SYR
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg of Guselkumab administered by subcutaneous injection
Trial: NCT05728528
Drug: pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
RxNorm normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone
Trial: NCT06789549
Drug: oxymetazoline nasal drops
RxNorm normalized name: oxymetazoline Nasal Solution
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in experimental arms received 1 mL of 0.1% oxymetazoline nasal drops before nasotracheal intubation
Trial: NCT06793228
Drug: Nanocrystalline Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanocrystalline Megestrol Acetate + Tislelizumab+ Chemotherapy (Carboplatin + Etoposide)
Trial: NCT06793228
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab combined with chemotherapy (Carboplatin + Etoposide)
Trial: NCT06793228
Drug: PTOC
RxNorm normalized name: Optochin
DrugBank: Mercaptocarboxylate Inhibitor (DB02706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocrystalline Megestrol Acetate+PD-(L)1 inhibitors+chemotherapy
Trial: NCT04634877
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT04634877
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04634877
Drug: Placebo for pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04634877
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
Trial: NCT04634877
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
Trial: NCT04634877
Drug: Cisplatin (as radiosensitizer)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29